ophthalmologytimes1d
Promising non-surgical treatment for early cataracts: Insights from a Phase II clinical trial
Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
Eyenovia to end eye drug study, cut 50% of its workforce
Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.
Eyenovia to end eye drug study after missing late-stage goal, shares fall
(Reuters) -Eyenovia will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness in children after it failed to slow the condition's progression, sending ...
AOL-reviewed: The Renpho eye massager has almost 17,000 five-star ratings, but is it really worth the hype?
We tried out the popular Renpho Eyeris eye massager to see if it's worth the hype. Turns out, it is. Here's why.
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...